Takeda K - Search Results

1

Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice.

Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Cretney E, et al. Among authors: takeda k. J Immunol. 2002 Feb 1;168(3):1356-61. doi: 10.4049/jimmunol.168.3.1356. J Immunol. 2002. PMID: 11801676

2

Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection.

Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda K, Yagita H, Smyth MJ. Kelly JM, et al. Among authors: takeda k. Nat Immunol. 2002 Jan;3(1):83-90. doi: 10.1038/ni746. Epub 2001 Dec 17. Nat Immunol. 2002. PMID: 11743585

3

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development.

Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, Okumura K. Takeda K, et al. J Exp Med. 2002 Jan 21;195(2):161-9. doi: 10.1084/jem.20011171. J Exp Med. 2002. PMID: 11805143 Free PMC article.

4

Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide.

Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, Takeda K, Yagita H, Godfrey DI. Smyth MJ, et al. Among authors: takeda k. Blood. 2002 Feb 15;99(4):1259-66. doi: 10.1182/blood.v99.4.1259. Blood. 2002. PMID: 11830474 Free article.

5

Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells.

Futagawa T, Akiba H, Kodama T, Takeda K, Hosoda Y, Yagita H, Okumura K. Futagawa T, et al. Among authors: takeda k. Int Immunol. 2002 Mar;14(3):275-86. doi: 10.1093/intimm/14.3.275. Int Immunol. 2002. PMID: 11867564

6

NKT cells - conductors of tumor immunity?

Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H, Godfrey DI. Smyth MJ, et al. Among authors: takeda k. Curr Opin Immunol. 2002 Apr;14(2):165-71. doi: 10.1016/s0952-7915(02)00316-3. Curr Opin Immunol. 2002. PMID: 11869887 Review.

7

A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo.

Kelly JM, Takeda K, Darcy PK, Yagita H, Smyth MJ. Kelly JM, et al. Among authors: takeda k. J Immunol. 2002 May 1;168(9):4472-9. doi: 10.4049/jimmunol.168.9.4472. J Immunol. 2002. PMID: 11970991

8

IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide.

Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K, Saiki I. Hayakawa Y, et al. Among authors: takeda k. Blood. 2002 Sep 1;100(5):1728-33. Blood. 2002. PMID: 12176894 Free article.

9

New aspects of natural-killer-cell surveillance and therapy of cancer.

Smyth MJ, Hayakawa Y, Takeda K, Yagita H. Smyth MJ, et al. Among authors: takeda k. Nat Rev Cancer. 2002 Nov;2(11):850-61. doi: 10.1038/nrc928. Nat Rev Cancer. 2002. PMID: 12415255 Review. No abstract available.

10

Nature's TRAIL--on a path to cancer immunotherapy.

Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H. Smyth MJ, et al. Among authors: takeda k. Immunity. 2003 Jan;18(1):1-6. doi: 10.1016/s1074-7613(02)00502-2. Immunity. 2003. PMID: 12530970 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,581 results

Search Page

Filters